Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 20/20 | 0.57 |
| ▸ | NTSR2 | O95665 | 17/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 15/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29737347 | 0.85 | NTSR2 (0.68) | NTSR1NTSR2SORT1 | |
| SCHEMBL31717953 | 0.84 | NTSR1 (0.56) | NTSR1NTSR2SORT1 | |
| SCHEMBL30437023 | 0.83 | CALCR (0.65) | — | |
| SCHEMBL31694383 | 0.83 | NTSR1 (0.68) | NTSR1NTSR2SORT1 | |
| Reltecimod SCHEMBL29430066 | 0.83 | CXCL8 (0.53) | NTSR1NTSR2 | |
| SCHEMBL29769336 | 0.83 | NTSR1 (0.59) | NTSR1NTSR2SORT1 | |
| SCHEMBL29802489 | 0.82 | SLC6A2 (0.60) | NTSR1NTSR2SORT1 | |
| SCHEMBL31679338 | 0.81 | SLC6A2 (0.60) | NTSR1NTSR2SORT1 | |
| SCHEMBL31378961 | 0.81 | NTSR1 (0.54) | NTSR1NTSR2SORT1 | |
| SCHEMBL30881987 | 0.81 | REN (0.59) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702461-B2 | T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides | CUE BIOPHARMA, INC. (US) | 2023-07-18 | — | — | US | claimed |
| US-12528839-B2 | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | VERIMMUNE, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250223320-A1 | HEPATITIS B VACCINES AND USES OF THE SAME | PRECIGEN, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12344637-B2 | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer | VERIMMUNE INC. | 2025-07-01 | — | — | US | disclosed |
| US-12234261-B2 | Hepatitis B vaccines and uses of the same | PRECIGEN, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240409606-A1 | T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240390473-A1 | CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES | VERIMMUNE INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240294577-A1 | VIRUS-INSPIRED COMPOSITIONS AND METHODS OF REDIRECTING PREEXISTING IMMUNE RESPONSES USING THE SAME FOR TREATMENT OF CANCER | VERIMMUNE INC. | 2024-09-05 | — | — | US | disclosed |
| US-12006348-B2 | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof | CUE BIOPHARMA, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11944677-B2 | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses | VERIMMUNE INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230279076-A1 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2023-09-07 | — | — | US | disclosed |
| US-11702461-B2 | T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides | CUE BIOPHARMA, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230201335-A1 | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4182465-A2 | T-CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4157349-A1 | ANTIGEN PRESENTING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11608362-B2 | Hepatitis B vaccines and uses of the same | PRECIGEN, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-11560408-B2 | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | VERIMMUNE INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220226460-A1 | CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES | VERIMMUNE INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220135624-A1 | VIRUS-INSPIRED COMPOSITIONS AND METHODS OF REDIRECTING PREEXISTING IMMUNE RESPONSES USING THE SAME FOR TREATMENT OF CANCER | VERIMMUNE INC. | 2022-05-05 | — | — | US | disclosed |
| US-11285203-B2 | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses | VERIMMUNE INC. (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006348-B2 | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof | IL2, CD4, HLA-DRB1 | NTSR1 956/4885NTSR2 404/4885SORT1 758/4885 |
| US-12528839-B2 | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | KLK3, KLKB1, CTSV | NTSR1 1181/4885NTSR2 2352/4885SORT1 1501/4885 |
| US-20240409606-A1 | T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof | IL2, CD4, HLA-DRB1 | NTSR1 956/4885NTSR2 404/4885SORT1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.